Jasper Therapeutics has reported complete responses in 10 of the 12 chronic hives patients who received the high dose of its c-Kit antibody. But, with some patients relapsing within weeks, the biotech has begun trialing a higher dose in pursuit of deeper, more durable responses.

The pattern goes as follows: roll out the data first, and then go to investors and ask for more money.

Three biotechs played right into that strategy on Tuesday.

The first was Jasper Therapeutics, which kicked things off Tuesday afternoon by announcing it plans on selling shares via a public offering. Jasper elaborated Wednesday morning, disclosing it would sell 60 million shares of stock at $1.50 each, for around $90 million. The stock $JSPR ticked up more than 10% after the opening bell.